Rosen Law Firm Promotes Inquiry into Potential Class Action for Soleno Therapeutics Shareholders
Rosen Law Firm, a prominent global investor rights law firm, has initiated an examination of potential securities claims on behalf of investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO). The firm’s investigation comes in response to allegations that Soleno Therapeutics may have given the public misleading information regarding its business operations leading to significant stock fluctuations. Investors are advised to consider their legal options, particularly those who have purchased Soleno Therapeutics’ securities. Under a contingency fee arrangement, eligible shareholders may seek compensation without incurring out-of-pocket expenses. The law firm aims to recover losses on behalf of affected investors through a class action lawsuit.
This recent development follows an article published on August 15, 2025, by Investing.com that disclosed a dramatic decline in Soleno Therapeutics stock, which dropped by 7.4% on that day alone. The decline was primarily attributed to a short report released by Scorpion Capital, which raised substantial concerns regarding the efficacy and safety of Soleno’s newly approved treatment for Prader-Willi syndrome, labeled VYKAT XR. The report suggested that the treatment could face possible market withdrawal or a severe reduction in new prescriptions due to highlighted personal safety issues.
Following the impact of this report, Soleno's shares fell further by 4.9% in the subsequent trading session, indicating a troubling trend for the company and its investors. Rosen Law Firm encourages those affected to act swiftly to join the prospective class action, which can be easily accessed through the firm’s official website, or by contacting the firm directly.
The Rosen Law Firm stands out for its historical success in securities class action lawsuits, having previously secured the largest ever settlement against a Chinese company. With its consistent track record of achieving favorable outcomes for investors, the firm has maintained a high ranking by ISS Securities Class Action Services, reflecting its experience and reputation in handling such cases. In 2019 alone, the firm recovered upwards of $438 million for various investors. Founding partner Laurence Rosen’s acclaim, being named a “Titan of the Plaintiffs' Bar” by Law360, underscores the firm's dedication to investor advocacy.
Shareholders of Soleno Therapeutics are advised to seek experienced legal counsel, especially given that not all firms in the sector possess comparable resources or expertise in navigating the complexities of securities class actions. Investing in the right legal support can be crucial for maximizing potential recovery.
Interested investors can follow the updates from Rosen Law Firm through their social media platforms, including LinkedIn, Twitter, and Facebook. For more information, shareholders can either visit the official website or contact attorneys at the firm directly.
This is an opportunity for Soleno Therapeutics investors to stand up for their rights amidst troubling circumstances surrounding the company’s stock performance. Taking action now could lead to significant recoveries for those affected by the recent developments concerning Soleno Therapeutics and its treatment product.
This recent development follows an article published on August 15, 2025, by Investing.com that disclosed a dramatic decline in Soleno Therapeutics stock, which dropped by 7.4% on that day alone. The decline was primarily attributed to a short report released by Scorpion Capital, which raised substantial concerns regarding the efficacy and safety of Soleno’s newly approved treatment for Prader-Willi syndrome, labeled VYKAT XR. The report suggested that the treatment could face possible market withdrawal or a severe reduction in new prescriptions due to highlighted personal safety issues.
Following the impact of this report, Soleno's shares fell further by 4.9% in the subsequent trading session, indicating a troubling trend for the company and its investors. Rosen Law Firm encourages those affected to act swiftly to join the prospective class action, which can be easily accessed through the firm’s official website, or by contacting the firm directly.
The Rosen Law Firm stands out for its historical success in securities class action lawsuits, having previously secured the largest ever settlement against a Chinese company. With its consistent track record of achieving favorable outcomes for investors, the firm has maintained a high ranking by ISS Securities Class Action Services, reflecting its experience and reputation in handling such cases. In 2019 alone, the firm recovered upwards of $438 million for various investors. Founding partner Laurence Rosen’s acclaim, being named a “Titan of the Plaintiffs' Bar” by Law360, underscores the firm's dedication to investor advocacy.
Shareholders of Soleno Therapeutics are advised to seek experienced legal counsel, especially given that not all firms in the sector possess comparable resources or expertise in navigating the complexities of securities class actions. Investing in the right legal support can be crucial for maximizing potential recovery.
Interested investors can follow the updates from Rosen Law Firm through their social media platforms, including LinkedIn, Twitter, and Facebook. For more information, shareholders can either visit the official website or contact attorneys at the firm directly.
This is an opportunity for Soleno Therapeutics investors to stand up for their rights amidst troubling circumstances surrounding the company’s stock performance. Taking action now could lead to significant recoveries for those affected by the recent developments concerning Soleno Therapeutics and its treatment product.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.